Announcements Trials

Browse Landscape

Phase

Phase 2 24 Phase 3 9 Phase 1 5 Phase 4 1 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 11 Esophageal Squamous Cell Carcinoma 8 Esophageal Neoplasms 7 Uterine Cervical Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 6 Nasopharyngeal Carcinoma 6 Lung Neoplasms 6 Head and Neck Neoplasms 5 Gallbladder Neoplasms 5 Cholangiocarcinoma 5 Pancreatic Neoplasms 4 Mesothelioma 4 Breast Neoplasms 4 Biliary Tract Neoplasms 4 Stomach Neoplasms 3 Oropharyngeal Neoplasms 3 Neoplasm Metastasis 3 Carcinoma 3 Urinary Bladder Neoplasms 2 Osteosarcoma 2 Neoplasms 2 Endometrial Neoplasms 2 Carcinoma, Transitional Cell 2 Carcinoma, Squamous Cell 2 Bile Duct Neoplasms 2 Adenocarcinoma Of Esophagus 2 Triple Negative Breast Neoplasms 1 Thymoma 1 Thymic epithelial tumor 1 Testicular Neoplasms 1

Interventions

Taxes 1 Specimen Handling 1 Radiotherapy 1 Radiation 1 Pharmacogenomic Testing 1 Pemetrexed 1 Paclitaxel 1 Nivolumab 1 Magnetic Resonance Spectroscopy 1 Ipilimumab 1 Cisplatin 1 Carboplatin 1 CTLA-4 Antigen 1 Biopsy 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Adenocarcinoma of Lung × Cisplatin × Clear all

NCT03380468 2023-07-20

ECTOP-1004

Fudan University

Phase 2/3 Unknown

Adenocarcinoma of Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡